{"transactions":[{"id":1671170,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Market Stock Unit","published_at":"2024-01-25T20:29:59.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":4803,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026."}],"balance_after":4803,"derivative":{"underlying":"Common Stock","underlying_shares":4803},"source":{"system":"sec-edgar","filing":"0000950170-24-007356","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024007356/ownership.xml","form_type":"4"}},{"id":1671169,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-25T20:29:59.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":7238,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":7238,"derivative":{"exercise_price":229,"expiration_date":"2031-01-23","underlying":"Common Stock","underlying_shares":7238},"source":{"system":"sec-edgar","filing":"0000950170-24-007356","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024007356/ownership.xml","form_type":"4"}},{"id":1671168,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-25T20:29:59.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":4803,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":18737,"source":{"system":"sec-edgar","filing":"0000950170-24-007356","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024007356/ownership.xml","form_type":"4"}},{"id":1676724,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-18T18:39:51.000Z","date":"2024-01-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":1067,"price":243.92,"value":260262.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents withholding of shares as payment of the Reporting Person's tax liabilities incident to the vesting of restricted stock units granted to the Reporting Person on January 16, 2023."}],"balance_after":13934,"source":{"system":"sec-edgar","filing":"0000950170-24-005289","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024005289/ownership.xml","form_type":"4"}},{"id":2052789,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-19T01:00:18.000Z","date":"2023-01-16","kind":"grant","acquired":true,"shares":15001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":15001,"source":{"system":"sec-edgar","filing":"0000899243-23-002096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323002096/doc4.xml","form_type":"4"}},{"id":2375356,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-25T01:40:51.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":45000,"derivative":{"exercise_price":87.09,"expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-22-007779","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322007779/doc4.xml","form_type":"4"}},{"id":2526930,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-03T20:26:32.000Z","date":"2021-11-01","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (11/1/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. This option was granted under our 2015 stock plan at a regularly scheduled meeting of the Compensation Committee of our Board of Directors on November 1, 2021."}],"balance_after":5000,"derivative":{"exercise_price":81.95,"expiration_date":"2031-11-01","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-21-042719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924321042719/doc4.xml","form_type":"4"}},{"id":2705860,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-19T19:40:28.000Z","date":"2021-05-17","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (05/17/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":65000,"derivative":{"exercise_price":134,"expiration_date":"2031-05-17","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000899243-21-019909","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924321019909/doc4.xml","form_type":"4"}},{"id":3008407,"issuer":{"id":145982,"kind":"organization","name":"AKCEA THERAPEUTICS, INC.","symbol":"AKCA"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-13T15:58:21.000Z","date":"2020-10-12","kind":"disposition_to_issuer","acquired":false,"shares":34200,"price":5.39,"value":184338.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $184,338.00, representing the difference between the exercise price of the option and the acquisition price of $18.15."}],"balance_after":0,"derivative":{"exercise_price":12.76,"expiration_date":"2030-03-18","underlying":"Common Stock","underlying_shares":34200},"source":{"system":"sec-edgar","filing":"0001209191-20-054615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1795798/000120919120054615/doc4.xml","form_type":"4"}},{"id":3008406,"issuer":{"id":145982,"kind":"organization","name":"AKCEA THERAPEUTICS, INC.","symbol":"AKCA"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-13T15:58:21.000Z","date":"2020-10-12","kind":"disposition_to_issuer","acquired":false,"shares":300000,"price":0.21,"value":63000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option, which provided that 25% of the shares would vest on December 2, 2020 and then in equal monthly installments over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $63,000.00, representing the difference between the exercise price of the option and the acquisition price of $18.15."}],"balance_after":0,"derivative":{"exercise_price":17.94,"expiration_date":"2029-12-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-20-054615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1795798/000120919120054615/doc4.xml","form_type":"4"}},{"id":3008405,"issuer":{"id":145982,"kind":"organization","name":"AKCEA THERAPEUTICS, INC.","symbol":"AKCA"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-10-13T15:58:21.000Z","date":"2020-10-12","kind":"other","acquired":false,"shares":66800,"price":18.15,"value":1212420.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-054615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1795798/000120919120054615/doc4.xml","form_type":"4"}},{"id":3198099,"issuer":{"id":145982,"kind":"organization","name":"AKCEA THERAPEUTICS, INC.","symbol":"AKCA"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-03-23T16:35:58.000Z","date":"2020-03-19","kind":"grant","acquired":true,"shares":34200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest as follows: 1/4th of the shares vest one year after March 19, 2020;1/48th of the shares vest monthly thereafter over the next three years."}],"balance_after":34200,"derivative":{"exercise_price":12.76,"expiration_date":"2030-03-18","underlying":"Common Stock","underlying_shares":34200},"source":{"system":"sec-edgar","filing":"0001209191-20-020647","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1795798/000120919120020647/doc4.xml","form_type":"4"}},{"id":3198098,"issuer":{"id":145982,"kind":"organization","name":"AKCEA THERAPEUTICS, INC.","symbol":"AKCA"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-03-23T16:35:58.000Z","date":"2020-03-19","kind":"grant","acquired":true,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2015 Equity Incentive Plan."}],"balance_after":66800,"source":{"system":"sec-edgar","filing":"0001209191-20-020647","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1795798/000120919120020647/doc4.xml","form_type":"4"}},{"id":3352743,"issuer":{"id":145982,"kind":"organization","name":"AKCEA THERAPEUTICS, INC.","symbol":"AKCA"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-12-04T16:08:26.000Z","date":"2019-12-02","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest as follows: 25% of the shares vest on December 2, 2020 and then in equal monthly installments over the next three years."}],"balance_after":300000,"derivative":{"exercise_price":17.94,"expiration_date":"2029-12-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-19-059037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1795798/000120919119059037/doc4.xml","form_type":"4"}},{"id":3352742,"issuer":{"id":145982,"kind":"organization","name":"AKCEA THERAPEUTICS, INC.","symbol":"AKCA"},"owners":[{"id":94906,"kind":"person","name":"Howarth Alex G.","position":1,"cik":"0001795798","reported_name":"Howarth Alex G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-12-04T16:08:26.000Z","date":"2019-12-02","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001209191-19-059037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1795798/000120919119059037/doc4.xml","form_type":"4"}}]}